Publication Name	World Journal of Gastroenterology
Manuscript ID	18335
Country	China

Received	2015-04-17 08:48
Peer-Review Started	2015-04-18 17:20
To Make the First Decision	2015-05-18 13:04
Return for Revision	2015-05-20 12:11
Revised	2015-06-19 10:56
Second Decision	2015-09-12 21:57
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-09-14 11:10
Articles in Press	2015-09-14 11:11
Publication Fee Transferred
Edit the Manuscript by Language Editor	2015-09-24 07:44
Typeset the Manuscript	2015-10-20 13:08
Publish the Manuscript Online	2015-11-03 17:31

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Inflammation: A novel target of current therapies for hepatic encephalopathy in liver cirrhosis
Manuscript Source	Invited Manuscript
All Author List	Ming Luo, Jian-Yang Guo and Wu-Kui Cao
Funding Agency and Grant Number
Corresponding Author	Wu-Kui Cao, PhD, Tianjin Liver Disease Institute, Tianjin Second People’s Hospital, No. 75 Sudi Road, Nankai District, Tianjin 300192, China. caowukui@126.com
Key Words	Inflammation; Hepatic encephalopathy; Pathogenesis; Treatment
Core Tip	Currently, inflammation appears to play a critical role in the pathogenesis of hepatic encephalopathy (HE) and is gradually being considered a critical therapeutic target for HE in patients with liver cirrhosis. Current therapies for HE, including lactulose, rifaximin, probiotics and the molecular adsorbent recirculating system, have been found to improve clinical manifestations and prevent the progression of HE by ameliorating inflammation in cirrhotic patients. This review will provide an overview of the inflammatory pathogenesis of HE, focusing on the recent findings on its therapeutic manipulation.
Publish Date	2015-11-03 17:31
Citation	Luo M, Guo JY, Cao WK. Inflammation: A novel target of current therapies for hepatic encephalopathy in liver cirrhosis. World J Gastroenterol 2015; 21(41): 11815-11824
URL	http://www.wjgnet.com/1007-9327/full/v21/i41/11815.htm
DOI	http://dx.doi.org/10.3748/wjg.v21.i41.11815

Full Article (PDF)	WJG-21-11815.pdf
Full Article (Word)	WJG-21-11815.doc
Manuscript File	18335-Review.docx
Answering Reviewers	18335-Answering reviewers.pdf
Audio Core Tip	18335-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	18335-Conflict-of-interest statement.pdf
Copyright License Agreement	18335-Copyright assignment.PDF
Non-Native Speakers of English Editing Certificate	18335-Language certificate.pdf
Peer-review Report	18335-Peer-review(s).pdf
Scientific Misconduct Check	18335-Scientific misconduct check.pdf
Scientific Editor Work List	18335-Scientific editor work list.pdf